Diaceutics (LON:DXRX) Hits New 12-Month High – What’s Next?

Diaceutics PLC (LON:DXRX) shares hit a new 52-week high during trading on Monday. The stock traded as high as GBX 210 and last traded at GBX 206.50, with a volume of 227,890 shares. The stock had previously closed at GBX 203.52.

Analyst Upgrades and Downgrades

Separately, Canaccord Genuity Group restated a “buy” rating and set a GBX 215 price target on shares of Diaceutics in a report on Tuesday, September 22nd. Two equities research analysts have rated the stock with a Buy rating. Based on data from MarketBeat, Diaceutics currently has an average rating of “Buy” and an average price target of GBX 215.

Diaceutics Stock Up 1.5%

The company has a market cap of £175.30 million, a price-to-earnings ratio of -645.31 and a beta of 0.88. The business has a 50-day simple moving average of GBX 168.39 and a two-hundred day simple moving average of GBX 157.80. The company has a quick ratio of 9.92, a current ratio of 2.55 and a debt-to-equity ratio of 5.40.

Diaceutics (LON:DXRX) last issued its quarterly earnings data on Tuesday, September 22nd. The company reported GBX (3.27) EPS for the quarter. Diaceutics had a negative net margin of 0.66% and a negative return on equity of 0.68%. As a group, equities analysts forecast that Diaceutics PLC will post 1.01 earnings per share for the current fiscal year.

Diaceutics Company Profile

At Diaceutics we believe that every patient should get the opportunity to receive the right test and the right therapy to positively impact their disease outcome. We provide the world’s leading pharma and biotech companies with an end-to-end commercialisation solution for precision medicines through data analytics, scientific and advisory services enabled by our platform DXRX – The Diagnostics Network®.